1. Home
  2. INTS vs DARE Comparison

INTS vs DARE Comparison

Compare INTS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.42

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Logo Dare Bioscience Inc.

DARE

Dare Bioscience Inc.

HOLD

Current Price

$2.28

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTS
DARE
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0M
24.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
INTS
DARE
Price
$0.42
$2.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$4.33
$10.00
AVG Volume (30 Days)
3.3M
233.9K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$3,924.12
Revenue Next Year
N/A
$8,523.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.61
52 Week High
$3.17
$9.19

Technical Indicators

Market Signals
Indicator
INTS
DARE
Relative Strength Index (RSI) 47.75 69.05
Support Level $0.46 $1.64
Resistance Level $0.54 $1.86
Average True Range (ATR) 0.06 0.14
MACD 0.00 0.08
Stochastic Oscillator 27.87 75.56

Price Performance

Historical Comparison
INTS
DARE

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Share on Social Networks: